Human Health Holdings Limited's (HKG:1419) CEO Might Not Expect Shareholders To Be So Generous This Year

Key Insights

• Human Health Holdings to hold its Annual General Meeting on 10th of December
• Salary of HK$4.63m is part of CEO Kin Ping Chan's total remuneration
• Total compensation is 172% above industry average
• Over the past three years, Human Health Holdings' EPS fell by 59% and over the past three years, the total loss to shareholders 46%

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Shareholders will probably not be too impressed with the underwhelming results at Human Health Holdings Limited (HKG:1419) recently. At the upcoming AGM on 10th of December, shareholders can hear from the board including their plans for turning around performance. It would also be an opportunity for shareholders to influence management through voting on company resolutions such as executive remuneration, which could impact the firm significantly. From our analysis, we think CEO compensation may need a review in light of the recent performance.

View our latest analysis for Human Health Holdings

How Does Total Compensation For Kin Ping Chan Compare With Other Companies In The Industry?

According to our data, Human Health Holdings Limited has a market capitalization of HK$315m, and paid its CEO total annual compensation worth HK$5.4m over the year to June 2025. Notably, that's an increase of 25% over the year before. In particular, the salary of HK$4.63m, makes up a huge portion of the total compensation being paid to the CEO.

In comparison with other companies in the Hong Kong Healthcare industry with market capitalizations under HK$1.6b, the reported median total CEO compensation was HK$2.0m. Hence, we can conclude that Kin Ping Chan is remunerated higher than the industry median. Moreover, Kin Ping Chan also holds HK$5.7m worth of Human Health Holdings stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

On an industry level, roughly 80% of total compensation represents salary and 20% is other remuneration. Our data reveals that Human Health Holdings allocates salary more or less in line with the wider market. If total compensation veers towards salary, it suggests that the variable portion - which is generally tied to performance, is lower.

A Look at Human Health Holdings Limited's Growth Numbers

Human Health Holdings Limited has reduced its earnings per share by 59% a year over the last three years. Its revenue is up 9.1% over the last year.

The decline in EPS is a bit concerning. And the modest revenue growth over 12 months isn't much comfort against the reduced EPS. These factors suggest that the business performance wouldn't really justify a high pay packet for the CEO. We don't have analyst forecasts, but you could get a better understanding of its growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

Has Human Health Holdings Limited Been A Good Investment?

With a total shareholder return of -46% over three years, Human Health Holdings Limited shareholders would by and large be disappointed. This suggests it would be unwise for the company to pay the CEO too generously.

To Conclude...

Along with the business performing poorly, shareholders have suffered with poor share price returns on their investments, suggesting that there's little to no chance of them being in favor of a CEO pay raise. At the upcoming AGM, they can question the management's plans and strategies to turn performance around and reassess their investment thesis in regards to the company.

While it is important to pay attention to CEO remuneration, investors should also consider other elements of the business. That's why we did some digging and identified 3 warning signs for Human Health Holdings that you should be aware of before investing.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.